Últimas noticias sobre Organon (NYSE:OGN) Bolsa

Organon

Organon & Co is a science-based global pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's operations include the following product portfolio: Women's health, Biosimilars, and Established medicines. Geographically, it derives a majority of its revenue from Europe and Canada followed by the United States and then Asia Pacific and Japan. The company generates the majority of its revenue from the Established Brands product portfolio.

Organon & Co

Origin Protocol - United States Dollar

OROGEN ROYALTIES INC by Orogen Royalties Inc.

Orogen Royalties Inc

ORGANA TECHS GRP INC by Organa Technologies Group, Inc.

<p>Stifel  analyst Jim Duffy   maintains Deckers Outdoor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DECK#NYSE">DECK</a>) with a Hold and raises the price target from $181 to $185.</p>


News

Price Target

Analyst Ratings

DECK

Stifel Maintains Hold on Deckers Outdoor, Raises Price Target to $185

<p>Stephens &amp; Co.  analyst Andrew Terrell   maintains FinWise (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FINW#NASDAQ">FINW</a>) with a Overweight and raises the price target from $20 to $22.</p>


FINW

Stephens & Co. Maintains Overweight on FinWise, Raises Price Target to $22

<p>Stifel  analyst Adam Borg   maintains Check Point Software (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHKP#NASDAQ">CHKP</a>) with a Hold and raises the price target from $190 to $220.</p>


CHKP

Stifel Maintains Hold on Check Point Software, Raises Price Target to $220

WIIM

Franklin Resources shares are trading higher after the company reported better-than-expected Q1 financial results.

<p>Stephens &amp; Co.  analyst Jeff Garro   maintains Veradigm (OTC:<a class="ticker" href="https://www.benzinga.com/stock/MDRX#OTC">MDRX</a>) with a Equal-Weight and raises the price target from $7 to $13.</p>


MDRX

Stephens & Co. Maintains Equal-Weight on Veradigm, Raises Price Target to $13

<p><strong>Walgreens Boots Alliance, Inc.</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBA#NASDAQ">WBA</a>) shares are moving lower on Friday after the company announced on Thursday that it suspended <a href="https://www.benzinga.com//node/43357768">its quarterly dividend</a>.</p>
<p><strong>What To Know:</strong> The company announced it is halting its quarterly dividend while the management team reviews and adjusts its capital allocation strategy to match the company&#8217;s broader long-term recovery efforts.</p>
<p>The goal is to enhance Walgreen&#8217;s financial position by prioritizing debt reduction and improving free cash flow. Furthermore, the company&#8217;s cash needs over the next several years, including those related to litigation and debt refinancing, were key factors in the decision to suspend the dividend.</p>
<p>Walgreens said in the press release that, &#8220;WBA leadership remains focused on successfully executing against its strategic priorities and maintaining financial discipline, which it believes will deliver sustained value creation over the long term.&#8221;</p>
<p><strong>How To Buy Walgreens Stock</strong></p>
<p>Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. </p>
<p>For example, in Walgreens Boots Alliance's case, it is in the Consumer Staples sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.</p>
<p><strong>See Also: <a href="https://www.benzinga.com/25/01/43391377/these-analysts-lower-their-forecasts-on-dow-after-downbeat-earnings">These Analysts Lower Their Forecasts On Dow After Downbeat Earnings</a></strong></p>
<p><strong>WBA Price Action:</strong> At the time of writing, Walgreens stock is trading 12.4% lower at $10.04, according to data from <a href="https://www.benzinga.com/pro/">Benzinga Pro.</a></p>
<p><em>Image: via Walgreens Boots Alliance</em>.</p>


Movers

What's Going On With Walgreens Shares Friday?

Politics

General

Chevron CEO Says He Welcomes Trump's Approach To Energy Policy

Global

Chevron CEO Says He Does Not See Company As A Power Merchant; Expects Argentina To Start Growing At A Stronger Rate Towards The Back End Of This Decade Than What's Been Seen Thus Far

<p>Benchmark  analyst Christopher Kuhn   reiterates Landstar System (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSTR#NASDAQ">LSTR</a>) from Hold to Hold.</p>


Reiteration

LSTR

Benchmark Reiterates Hold on Landstar Systemto Hold

<p>Whales with a lot of money to spend have taken a noticeably bearish stance on <strong>ServiceNow</strong>.</p>
<p>Looking at options history for ServiceNow (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOW#NYSE">NOW</a>) we detected 60 trades.</p>
<p>If we consider the specifics of each trade, it is accurate to state that 35% of the investors opened trades with bullish expectations and 40% with bearish.</p>
<p>From the overall spotted trades, 19 are puts, for a total amount of $2,502,956 and 41, calls, for a total amount of $2,982,640.</p>
<h3>Expected Price Movements</h3>
<p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $500.0 and $1340.0 for ServiceNow, spanning the last three months.</p>
<h3>Insights into Volume &amp; Open Interest</h3>
<p>Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for ServiceNow's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across ServiceNow's significant trades, within a strike price range of $500.0 to $1340.0, over the past month.</p>
<h3>ServiceNow 30-Day Option Volume &amp; Interest Snapshot</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1738341122_0.png" alt="Options Call Chart" /></p>
<h3>Significant Options Trades Detected:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th align="right"><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>NOW</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/31/25</td>
<td>$66.0</td>
<td>$59.2</td>
<td>$64.0</td>
<td>$1090.00</td>
<td>$320.0K</td>
<td align="right">89</td>
<td align="right">4</td>
</tr>
<tr>
<td>NOW</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$555.0</td>
<td>$550.0</td>
<td>$550.0</td>
<td>$500.00</td>
<td>$275.0K</td>
<td align="right">17</td>
<td align="right">5</td>
</tr>
<tr>
<td>NOW</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$66.0</td>
<td>$65.6</td>
<td>$66.0</td>
<td>$1000.00</td>
<td>$250.8K</td>
<td align="right">474</td>
<td align="right">186</td>
</tr>
<tr>
<td>NOW</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>08/15/25</td>
<td>$84.5</td>
<td>$79.5</td>
<td>$81.0</td>
<td>$1000.00</td>
<td>$202.5K</td>
<td align="right">25</td>
<td align="right">25</td>
</tr>
<tr>
<td>NOW</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$57.2</td>
<td>$51.2</td>
<td>$55.0</td>
<td>$1010.00</td>
<td>$192.5K</td>
<td align="right">133</td>
<td align="right">75</td>
</tr>
</tbody>
</table>
</p>
<h3>About ServiceNow</h3>
<p>ServiceNow Inc provides software solutions to structure and automate various business processes via a SaaS delivery model. The company primarily focuses on the IT function for enterprise customers. ServiceNow began with IT service management, expanded within the IT function, and more recently directed its workflow automation logic to functional areas beyond IT, notably customer service, HR service delivery, and security operations. ServiceNow also offers an application development platform as a service.</p>
<p>Having examined the options trading patterns of ServiceNow, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance</p>
<h3>ServiceNow's Current Market Status</h3>
<ul>
<li>With a trading volume of 1,006,658, the price of NOW is up by 1.65%, reaching $1029.44.</li>
<li>Current RSI values indicate that the stock is is currently neutral between overbought and oversold.</li>
<li>Next earnings report is scheduled for 82 days from now.</li>
</ul>
<h3>Expert Opinions on ServiceNow</h3>
<p>A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $1235.0.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; Consistent in their evaluation, an analyst from JMP Securities keeps a Market Outperform rating on ServiceNow with a target price of $1300.<br />
&#x2A; An analyst from Canaccord Genuity persists with their Buy rating on ServiceNow, maintaining a target price of $1275.<br />
&#x2A; An analyst from Baird has decided to maintain their Outperform rating on ServiceNow, which currently sits at a price target of $1200.<br />
&#x2A; Consistent in their evaluation, an analyst from Needham keeps a Buy rating on ServiceNow with a target price of $1200.<br />
&#x2A; Consistent in their evaluation, an analyst from Piper Sandler keeps a Overweight rating on ServiceNow with a target price of $1200. </p>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for ServiceNow with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.</p>


Options

Markets

ServiceNow Options Trading: A Deep Dive into Market Sentiment

<p>Investors with a lot of money to spend have taken a bullish stance on <strong>Palantir Technologies</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>).</p>
<p>And retail traders should know.</p>
<p>We noticed this today when the positions showed up on publicly available options history that we track here at Benzinga.</p>
<p>Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with PLTR, it often means somebody knows something is about to happen.</p>
<p>Today, Benzinga's options scanner spotted 31 options trades for <strong>Palantir Technologies</strong>.</p>
<p>This isn't normal.</p>
<p>The overall sentiment of these big-money traders is split between 54% bullish and 38%, bearish.</p>
<p>Out of all of the options we uncovered, there was 1 put, for a total amount of $53,200, and 30, calls, for a total amount of $2,164,639.</p>
<h3>Expected Price Movements</h3>
<p>Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $22.0 to $115.0 for Palantir Technologies over the last 3 months. </p>
<h3>Volume &amp; Open Interest Development</h3>
<p>Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.</p>
<p>This data can help you track the liquidity and interest for Palantir Technologies's options for a given strike price.</p>
<p>Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Palantir Technologies's whale activity within a strike price range from $22.0 to $115.0 in the last 30 days. </p>
<h3>Palantir Technologies Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1738341117_0.png" alt="Options Call Chart" /></p>
<h3>Noteworthy Options Activity:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>PLTR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/21/25</td>
<td>$18.1</td>
<td>$17.0</td>
<td>$17.0</td>
<td>$95.00</td>
<td>$510.0K</td>
<td>3</td>
<td>355</td>
</tr>
<tr>
<td>PLTR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$11.75</td>
<td>$11.65</td>
<td>$11.74</td>
<td>$80.00</td>
<td>$240.8K</td>
<td>12.4K</td>
<td>1.6K</td>
</tr>
<tr>
<td>PLTR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>03/21/25</td>
<td>$15.4</td>
<td>$15.2</td>
<td>$15.35</td>
<td>$70.00</td>
<td>$156.5K</td>
<td>8.5K</td>
<td>103</td>
</tr>
<tr>
<td>PLTR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/31/25</td>
<td>$2.7</td>
<td>$2.58</td>
<td>$2.61</td>
<td>$82.00</td>
<td>$147.0K</td>
<td>9.5K</td>
<td>8.9K</td>
</tr>
<tr>
<td>PLTR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/31/25</td>
<td>$0.93</td>
<td>$0.89</td>
<td>$0.91</td>
<td>$84.00</td>
<td>$89.9K</td>
<td>8.7K</td>
<td>10.5K</td>
</tr>
</tbody>
</table>
</p>
<h3>About Palantir Technologies</h3>
<p>Palantir is an analytical software company that focuses on leveraging data to create efficiencies in its clients' organizations. The firm serves commercial and government clients via its Foundry and Gotham platforms, respectively. The Denver-based company was founded in 2003 and went public in 2020.</p>
<p>Having examined the options trading patterns of Palantir Technologies, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance</p>
<h3>Palantir Technologies's Current Market Status</h3>
<ul>
<li>With a volume of 31,097,524, the price of PLTR is down -0.12% at $81.12. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 3 days.</li>
</ul>
<h3>Professional Analyst Ratings for Palantir Technologies</h3>
<p>3 market experts have recently issued ratings for this stock, with a consensus target price of $74.0.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from Cantor Fitzgerald has revised its rating downward to Neutral, adjusting the price target to $72.<br />
&#x2A; Consistent in their evaluation, an analyst from Wedbush keeps a Outperform rating on Palantir Technologies with a target price of $90.<br />
&#x2A; In a cautious move, an analyst from Morgan Stanley downgraded its rating to Underweight, setting a price target of $60. </p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Palantir Technologies, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.</p>


PLTR

Palantir Technologies's Options Frenzy: What You Need to Know

<p>Whales with a lot of money to spend have taken a noticeably bearish stance on <strong>Affirm Holdings</strong>.</p>
<p>Looking at options history for Affirm Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFRM#NASDAQ">AFRM</a>) we detected 18 trades.</p>
<p>If we consider the specifics of each trade, it is accurate to state that 33% of the investors opened trades with bullish expectations and 66% with bearish.</p>
<p>From the overall spotted trades, 4 are puts, for a total amount of $170,690 and 14, calls, for a total amount of $893,344.</p>
<h3>What's The Price Target?</h3>
<p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $35.0 to $73.0 for Affirm Holdings during the past quarter. </p>
<h3>Analyzing Volume &amp; Open Interest</h3>
<p>In today's trading context, the average open interest for options of Affirm Holdings stands at 1176.64, with a total volume reaching 1,795.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Affirm Holdings, situated within the strike price corridor from $35.0 to $73.0, throughout the last 30 days.</p>
<h3>Affirm Holdings Option Activity Analysis: Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1738341112_0.png" alt="Options Call Chart" /></p>
<h3>Noteworthy Options Activity:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>AFRM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$24.85</td>
<td>$23.7</td>
<td>$23.7</td>
<td>$40.00</td>
<td>$130.3K</td>
<td>1.8K</td>
<td align="right">0</td>
</tr>
<tr>
<td>AFRM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$15.8</td>
<td>$15.65</td>
<td>$15.65</td>
<td>$52.50</td>
<td>$114.2K</td>
<td>514</td>
<td align="right">93</td>
</tr>
<tr>
<td>AFRM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>02/07/25</td>
<td>$4.65</td>
<td>$4.55</td>
<td>$4.55</td>
<td>$63.00</td>
<td>$91.0K</td>
<td>248</td>
<td align="right">26</td>
</tr>
<tr>
<td>AFRM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$15.65</td>
<td>$15.6</td>
<td>$15.6</td>
<td>$52.50</td>
<td>$81.1K</td>
<td>514</td>
<td align="right">93</td>
</tr>
<tr>
<td>AFRM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$11.45</td>
<td>$11.25</td>
<td>$11.32</td>
<td>$55.00</td>
<td>$76.9K</td>
<td>2.3K</td>
<td align="right">91</td>
</tr>
</tbody>
</table>
</p>
<h3>About Affirm Holdings</h3>
<p>Affirm Holdings Inc offers a platform for digital and mobile-first commerce. It comprises a point-of-sale payment solution for consumers, merchant commerce solutions, and a consumer-focused app. The firm generates its revenue from merchant networks, and through virtual card networks among others. Geographically, it generates a majority share of its revenue from the United States.</p>
<p>After a thorough review of the options trading surrounding Affirm Holdings, we move to examine the company in more detail. This includes an assessment of its current market status and performance.</p>
<h3>Current Position of Affirm Holdings</h3>
<ul>
<li>With a volume of 1,338,908, the price of AFRM is up 0.74% at $62.56. </li>
<li>RSI indicators hint that the underlying stock is currently neutral between overbought and oversold.</li>
<li>Next earnings are expected to be released in 6 days.</li>
</ul>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.</p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Affirm Holdings, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.</p>


AFRM

Unpacking the Latest Options Trading Trends in Affirm Holdings

Eastman Chemical shares are trading higher after the company reported better-than-expected Q4 adjusted EPS results.

<p>Benchmark  analyst Christopher Kuhn   reiterates C.H. Robinson Worldwide (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHRW#NASDAQ">CHRW</a>) with a Buy and maintains $125 price target.</p>


CHRW

Benchmark Reiterates Buy on C.H. Robinson Worldwide, Maintains $125 Price Target

Events

Live On CNBC, Palantir CEO Alex Karp Says "America Has The Single Best Tech Scene In The World"; "Supportive Of Acting Through Foreign Policy"

SES AI shares are trading higher after the company provided preliminary Q4 financial results.

Cigna shares are trading higher, rebounding after falling Thursday on a Q4 earnings miss.

<p>Gilead Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) has outperformed the market over the past 20 years by 4.84% on an annualized basis producing an average annual return of 13.3%. Currently, Gilead Sciences has a market capitalization of $121.75 billion. </p>
<p><strong>Buying $100 In GILD:</strong> If an investor had bought $100 of GILD stock 20 years ago, it would be worth <strong>$1,201.60</strong> today based on a price of $97.69 for GILD at the time of writing.</p>
<h3>Gilead Sciences's Performance Over Last 20 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1738341013_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Trading Ideas

GILD

$100 Invested In This Stock 20 Years Ago Would Be Worth This Much Today

Guidance

LyondellBasell CFO Says Co Will Defer Some Growth Investments Until Later In The Decade

<p>Benchmark  analyst David Williams   reiterates MaxLinear (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MXL#NASDAQ">MXL</a>) with a Buy and maintains $28 price target.</p>


Benchmark Reiterates Buy on MaxLinear, Maintains $28 Price Target

Organon gets expanded FDA approval for VTAMA

Goldman Sachs raised the firm's price target on Organon (OGN) to $20 from $19 and keeps a Neutral rating on the shares. The firm cites the company'...

Organon price target raised to $20 from $19 at Goldman Sachs

Organon snaps six days of winning streak

Organon & Co. (OGN) JPMorgan Annual Healthcare Conference - (Transcript)

In a report released today, Steve Scala from TD Cowen maintained a Hold rating on Organon (OGN – Research Report), with a price target of $19.00. S...

Cautious Outlook for Organon Amidst Upcoming Launches and Future Challenges

TD Cowen analyst Michael Nedelcovych took over primary coverage of Organon (OGN) with a Hold rating and $19 price target Organon presented business...

Organon transferred with a Hold at TD Cowen

AbbVie retains Humira market share above 70%: report

Organon: A Tricky 2025 Awaits, But I'm Happy With A >7% Dividend Yield

Top 4 Immunology Stocks Poised For Growth In 2025

Organon ( ($OGN) ) just unveiled an update. On January 15, 2025, Organon & Co. announced the cessation of Susanne Fiedler's role as Chief Commercia...

Organon Announces Cessation of Chief Commercial Officer Role

ABBV

ALVO

ALVOW

AMGN

ARGX

AZNCF

BIIB

BMYMP

CGEM

CHRS

FBCG

GLAXF

IFRX

INCY

REGN

RHHBF

RHHBY

RHHVF

ROIV

SDZNY

SDZXF

SNYNF

TEVA

TEVJF

TKPHF

VTRS

Press Releases

Organon Canada Promotes Geneviève Gauthier as Executive Director, Corporate Affairs and Community Engagement and Appoints Jeffrey Malawski as Executive Director, Women's Health and Established Brands

Organon to Report Third Quarter 2024 Results and Host Conference Call on October 31, 2024

Organon Completes Acquisition of Dermavant, including Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%

US FDA Accepts Biologics License Application (BLA) for HLX14, Biosimilar Candidate of PROLIA/XGEVA (denosumab)

Organon Reports Results for the Third Quarter Ended September 30, 2024

Update on FDA Review of VTAMA® (tapinarof) Cream, 1% for the Treatment of Atopic Dermatitis in Adults and Children 2 Years of Age and Older

FDA Approves VTAMA® (tapinarof) cream, 1% for the Treatment of Atopic Dermatitis in Adults and Children 2 Years of Age and Older

Organon To Present at the 43rd Annual J.P. Morgan Healthcare Conference

Organon To Report Fourth Quarter and Full Year 2024 Results and Host Conference Call on February 13, 2025

ROIVW

Amneal Pharmaceuticals, Inc. - Class A Common Stock

Amneal Pharmaceuticals

Axsome Therapeutics

AstraZeneca PLC - American Depositary Shares

AstraZeneca

Bristol-Myers Squibb Company Common Stock

Bristol-Myers Squibb

Corcept Therapeutics Incorporated - Common Stock

Corcept Therapeutics

Elanco Animal Health Incorporated Common Stock

Elanco Animal Health

Edgewise Therapeutics, Inc. - Common Stock

Edgewise Therapeutics

GSK plc American Depositary Shares (Each representing two Ordinary Shares)

Intra-Cellular Therapies Inc. - Common Stock

Intra-Cellular Therapies

Jazz Pharmaceuticals plc - Ordinary Shares

Jazz Pharmaceuticals

Johnson & Johnson

Eli Lilly

Merck & Co

Novo Nordisk

Novartis

Prestige Consumer Healthcare Inc. Common Stock

Prestige Consumer

Pfizer

Dr. Reddy's Laboratories Ltd Common Stock

Dr Reddy's Laboratories

Royalty Pharma plc - Class A Ordinary Shares

Royalty Pharma

Sanofi

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

Comments

Organon

Noticias

Últimas noticias sobre Organon (NYSE:OGN) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL